As big an issue as it has become, compliance is the least of life sciences companies’ concerns as 2016 gives way to 2017. But the right approach will equip companies to successfully navigate everything from market consolidation and new market entry to marketing innovation and operational transparency, which will set them in good stead for years to come, says Adam Sherlock, CEO of ProductLife Group.
https://international-pharma.com/wp-content/uploads/2016/12/Tipping-point.pdf
https://international-pharma.com/wp-content/uploads/2016/12/Tipping-point.pdf